Halozyme Therapeutics/$HALO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Halozyme Therapeutics
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Ticker
$HALO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
350
ISIN
US40637H1095
Website
HALO Metrics
BasicAdvanced
$6.6B
14.30
$3.76
1.26
-
Price and volume
Market cap
$6.6B
Beta
1.26
52-week high
$70.51
52-week low
$42.01
Average daily volume
2.7M
Financial strength
Current ratio
8.392
Quick ratio
6.999
Long term debt to equity
318.667
Total debt to equity
318.667
Interest coverage (TTM)
32.99%
Management effectiveness
Return on assets (TTM)
18.49%
Return on equity (TTM)
147.06%
Valuation
Price to earnings (TTM)
14.3
Price to revenue (TTM)
6.241
Price to book
13.73
Price to tangible book (TTM)
-20.78
Price to free cash flow (TTM)
13.65
Growth
Revenue change (TTM)
25.65%
Earnings per share change (TTM)
55.39%
3-year revenue growth (CAGR)
31.99%
3-year earnings per share growth (CAGR)
7.82%
What the Analysts think about HALO
Analyst ratings (Buy, Hold, Sell) for Halozyme Therapeutics stock.
HALO Financial Performance
Revenues and expenses
HALO Earnings Performance
Company profitability
HALO News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Halozyme Therapeutics stock?
Halozyme Therapeutics (HALO) has a market cap of $6.6B as of May 23, 2025.
What is the P/E ratio for Halozyme Therapeutics stock?
The price to earnings (P/E) ratio for Halozyme Therapeutics (HALO) stock is 14.3 as of May 23, 2025.
Does Halozyme Therapeutics stock pay dividends?
No, Halozyme Therapeutics (HALO) stock does not pay dividends to its shareholders as of May 23, 2025.
When is the next Halozyme Therapeutics dividend payment date?
Halozyme Therapeutics (HALO) stock does not pay dividends to its shareholders.
What is the beta indicator for Halozyme Therapeutics?
Halozyme Therapeutics (HALO) has a beta rating of 1.26. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.